Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

ClinicalTrials.gov ID: NCT06357533

Public ClinicalTrials.gov record NCT06357533. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

Study identification

NCT ID: NCT06357533
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 675 participants

Conditions and interventions

Conditions

Non-Small Cell Lung Cancer

Interventions

Datopotamab Deruxtecan Drug
Pembrolizumab Drug
Rilvegostomig Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 10, 2024
Primary completion: Dec 27, 2029
Completion: Dec 27, 2029
Last update posted: Mar 15, 2026

2024 – 2029

United States locations

U.S. sites: 62
U.S. states: 29
U.S. cities: 56

Facility	City	State	ZIP	Site status
Research Site	Anchorage	Alaska	99508	Recruiting
Research Site	Tucson	Arizona	85719	Recruiting
Research Site	Little Rock	Arkansas	72205	Recruiting
Research Site	Springdale	Arkansas	72762	Recruiting
Research Site	Anaheim	California	92801	Recruiting
Research Site	Beverly Hills	California	90211	Recruiting
Research Site	Fountain Valley	California	92708	Recruiting
Research Site	Newport Beach	California	92663	Not yet recruiting
Research Site	Clermont	Florida	34711	Recruiting
Research Site	Gainesville	Florida	32608	Recruiting
Research Site	Miami Beach	Florida	33140	Recruiting
Research Site	Orange City	Florida	32763	Recruiting
Research Site	Orlando	Florida	32806	Not yet recruiting
Research Site	Orlando	Florida	32827	Withdrawn
Research Site	West Palm Beach	Florida	33401	Recruiting
Research Site	Atlanta	Georgia	30303	Not yet recruiting
Research Site	Atlanta	Georgia	30318	Recruiting
Research Site	Atlanta	Georgia	30322	Recruiting
Research Site	Atlanta	Georgia	30342	Withdrawn
Research Site	Hinsdale	Illinois	60521	Recruiting
Research Site	Noblesville	Indiana	46062	Recruiting
Research Site	Paducah	Kentucky	42003	Not yet recruiting
Research Site	Annapolis	Maryland	21401	Recruiting
Research Site	Boston	Massachusetts	02114	Recruiting
Research Site	Boston	Massachusetts	02215	Recruiting
Research Site	Dearborn	Michigan	48126	Recruiting
Research Site	Farmington Hills	Michigan	48334	Recruiting
Research Site	Grand Rapids	Michigan	49503	Recruiting
Research Site	Traverse City	Michigan	49684	Withdrawn
Research Site	Hattiesburg	Mississippi	39401	Recruiting
Research Site	Kansas City	Missouri	64132	Recruiting
Research Site	Bozeman	Montana	59715	Withdrawn
Research Site	Grand Island	Nebraska	68803	Recruiting
Research Site	Omaha	Nebraska	68130	Recruiting
Research Site	Las Vegas	Nevada	89102	Recruiting
Research Site	Reno	Nevada	89502	Withdrawn
Research Site	Voorhees Township	New Jersey	08043	Suspended
Research Site	Stony Brook	New York	11794	Recruiting
Research Site	Greenville	North Carolina	27834	Not yet recruiting
Research Site	Salisbury	North Carolina	28144	Recruiting
Research Site	Cincinnati	Ohio	45219	Recruiting
Research Site	Columbus	Ohio	43210	Withdrawn
Research Site	Maumee	Ohio	43537	Recruiting
Research Site	Toledo	Ohio	43623	Recruiting
Research Site	Portland	Oregon	97213	Withdrawn
Research Site	Greenville	South Carolina	29607	Recruiting
Research Site	Sioux Falls	South Dakota	57105	Recruiting
Research Site	Chattanooga	Tennessee	37404	Withdrawn
Research Site	Knoxville	Tennessee	37920	Withdrawn
Research Site	Fort Worth	Texas	76104	Recruiting
Research Site	Houston	Texas	77030	Withdrawn
Research Site	Houston	Texas	77090	Suspended
Research Site	Kingwood	Texas	77339	Recruiting
Research Site	Odessa	Texas	79761	Recruiting
Research Site	Fort Belvoir	Virginia	22060	Recruiting
Research Site	Leesburg	Virginia	20176	Recruiting
Research Site	Midlothian	Virginia	23114	Not yet recruiting
Research Site	Richmond	Virginia	23230	Recruiting
Research Site	Tacoma	Washington	98405	Recruiting
Research Site	Vancouver	Washington	98684	Recruiting
Research Site	Wenatchee	Washington	98801	Recruiting
Research Site	Appleton	Wisconsin	54911	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 215 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06357533, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 15, 2026 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06357533 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →